References
- Barbey JT, Roose SP. SSRI safety in overdose. J Clin Psychiatry 1998; 59(Suppl 15): 42–8.
- Olsen DG, Dart RC, Robinett M. Severe serotonin syndrome from escitalopram overdose [abstract]. Clin Toxicol 2004; 42: 744.
- Isbister GK, Bowe SJ, Dawson A, et al. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol 2004; 42(3): 277–85. [CrossRef]
- Scharko AM, Schumacher J. Prolonged QTc interval in a 14-year-old girl with escitalopram overdose. J Child Adolesc Psychopharmacol 2008; 18(3): 297–8. [CrossRef]
- Yuksel FV, Tuzer V, Goka E. Escitalopram intoxication. Eur Psychiatry 2005; 20(1): 82. [CrossRef]
- Baranchuk A, Simpson CS, Methot M, et al. Corrected QT interval prolongation after an overdose of escitalopram, morphine, oxycodone, zopiclone and benzodiazepines. Can J Cardiol 2008; 24(7): e38–e40. [CrossRef]
- Huska MT, Catalano G, Catalano MC. Serotonin syndrome associated with the use of escitalopram. CNS Spectr 2007; 12(4): 270–4.
- Forrester MB. Escitalopram ingestions reported to Texas poison control centers, 2002–2005. Hum Exp Toxicol 2007; 26(6): 473–82. [CrossRef]
- Beyenburg S, Schönegger K. Severe Bradycardia in a Stroke Patient Caused by a Single Low Dose of Escitalopram. Eur Neurol 2007; 57(1): 50–1. [CrossRef]
- van Gorp F, Whyte IM, Isbister GK. Clinical and ECG Effects of Escitalopram Overdose. Ann Emerg Med 2009; 54(3): 404–8. [CrossRef]
- Chan A, Isbister GK, Kirkpatrick CM, et al. Drug-induced QT prolongation and torsades de pointes: evaluation of a QT nomogram. QJM 2007; 100(10): 609–15. [CrossRef]
- Isbister GK, Friberg LE, Stokes B, et al. Activated charcoal decreases the risk of QT prolongation after citalopram overdose. Ann Emerg Med 2007; 50(5): 593–600. [CrossRef]
- Friberg LE, Isbister GK, Duffull SB. Pharmacokinetic pharmacodynamic modelling of QT interval prolongation following citalopram overdoses. Br J Clin Pharmacol 2006; 61(2): 177–90. [CrossRef]
- Kurdyak PA, Manno M, Gomes T, et al. Antidepressants, metoprolol and the risk of bradycardia. Ther Adv Psychopharmacol 2012; 2(2): 43–9. [CrossRef]